

A NOVEL BLOOD TEST
FOR THE EARLY
DIAGNOSIS OF
ENDOMETRIOSIS

PromarkerEndo

powered by Proteomics International



Correctly identified up to 90% of patients with the disease

Over 1,000 patients studied

Early screening could rule in or out the need for invasive surgery

Endometriosis



- **Common and often painful disease where endometrial-like tissue grows into other organs**

- **Affects 1 in 9 women and girls**

- **Diagnosis takes on average 7 years and requires invasive surgery**

- **Major cause of female infertility, and individuals can suffer from intense and chronic pain which substantially impacts quality of life¹**

- **Annual costs estimated at up to \$9.7 billion in Australia⁴, £8.2 billion in the UK³ and USD \$119 billion in the USA², in loss of work and healthcare costs**



Current Diagnosis

- **Gold-standard is laparoscopy with histological verification by a pathologist - invasive and costly**
- **50% of stage 1 endometriosis cases are missed in surgical diagnosis - most prevalent stage⁵**



Significant time and cost to patients with repeated doctor consults and many patients paying out of pocket for laparoscopy



A non-invasive blood test is in high demand

A NOVEL BLOOD TEST FOR THE EARLY DIAGNOSIS OF ENDOMETRIOSIS

PromarkerEndo


powered by Proteomics International

The PromarkerEndo test combines the concentration of blood-based protein biomarkers with age and BMI using a bi-model algorithm

The PromarkerEndo prototype test provided a
Sensitivity (Sn) of 90% and Specificity (Sp) of 90%

Clinical Studies and Collaborations

- ✓ **Discovery** - Wesley Medical Research Biobank (n=56 samples)
- ✓ **Analytical validation** - Royal Women's Hospital and University of Melbourne (n=700 patients; including endometriosis confirmed by laparoscopy and symptomatic controls)
- ✓ **Validation** - Healthy volunteers (n=153 samples)
- ✓ **Clinical validation** - St John of God Subiaco Hospital Gynecological Cancer Research Group (n=241 patients)
- ✓ **Clinical validation** - University of Oxford, Nuffield Dept. of Women's and Reproductive Health (n=606 patients)



Prototype test developed using a **traffic-light approach** to diagnose persons as **low, moderate or high likelihood of moderate/severe endometriosis** (n=164) from **symptomatic controls** (n=254)

REVOLUTIONISING THE DIAGNOSIS OF ENDOMETRIOSIS

Endometriosis

PromarkerEndo

Esophageal Cancer

PromarkerEso

Diabetic Kidney Disease

PromarkerD

Subscribe to updates on
PromarkerEndo



Proteomics International
LABORATORIES LTD

6 Verdun Street, Perth, WA, 6009

+61 8 9389 1992

www.proteomics.com.au

@proteomicsi

PromarkerEndo@proteomics.com.au

References:

- [1] Endometriosis, World Health Organization (WHO.org)
- [2] Endometriosis, Economic burden - Australian Institute of Health and Welfare (aihw.gov.au)
- [3] Endometriosis UK, Facts and Figures - Endometriosis-UK.org
- [4] Endometriosis Is Undervalued: A Call to Action, DOI: 10.3389/fgwh.2022.902371
- [5] Reliability of visual diagnosis of Endometriosis, DOI: 10.1016/j.jmig.2013.04.017